Oral Cavity Squamous Cell Carcinoma; ReadmissionNCT06259838
Oral Cavity Squamous Cell Carcinoma and Readmission: Rates, Causes, and Risk Factors.
An observational study of Oral Cavity Squamous Cell Carcinoma; Readmission, run by Abdulsalam Alqutub at 1 site in Saudi Arabia.
Trial summary
We sought to comprehend the rates and causes of unplanned hospital readmission within 60 days following oral cancer surgery Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Oral Cavity Squamous Cell Carcinoma; Readmission
- How many people
- 93 participants
- Where
- 1 siteSaudi Arabia
- Study dates
- 1 Jan 2023to 7 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: all patient underwent oral cancer surgery in king Abdulaziz University hospital
Who may be able to join
- all patient underwent oral cancer surgery in king Abdulaziz University hospital
Who cannot join
- significant missing data
Trial locations and contacts
1 site in 1 country.
About this study
We sought to comprehend the rates and causes of unplanned hospital readmission within 60 days following oral cancer surgery
- Being tested
- no intervention
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no interventionOther
no intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
rate of readmission
the number of readmitted patients within 60 days following oral cancer surgery
Measured: 60 days after discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2024
- Study start1 Jan 2023
- Primary completion27 Dec 2023
- Study completion7 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral Cavity Squamous Cell Carcinoma; ReadmissionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 93 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abdulsalam Alqutub
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Abdulsalam Alqutub, King Abdulaziz University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06259838
- Sponsor's protocol ID
- KingAbdulazizUn
- Status last verified
- Feb 2024
- First submitted
- 7 Feb 2024
- Last updated
- 14 Feb 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oral Cavity Squamous Cell Carcinoma and Readmission: Rates, Causes, and Risk Factors.
- ClinicalTrials.gov ID
- NCT06259838
- Acronym / sponsor ID
- KingAbdulazizUn
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 93 participants (actual)
- Lead sponsor
- Abdulsalam AlqutubUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 27 Dec 2023 (actual)
- Study completion
- 7 Feb 2024 (actual)
- First posted
- 14 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We sought to comprehend the rates and causes of unplanned hospital readmission within 60 days following oral cancer surgery
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- all patient underwent oral cancer surgery in king Abdulaziz University hospital
Key inclusion criteria (1 listed)
- all patient underwent oral cancer surgery in king Abdulaziz University hospital
Key exclusion criteria (1 listed)
- significant missing data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no interventionno intervention | Other | – |
Primary outcome
rate of readmission
Time frame: 60 days after discharge
the number of readmitted patients within 60 days following oral cancer surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2024.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oral Cavity Squamous Cell Carcinoma; Readmission, run by Abdulsalam Alqutub at 1 site in Saudi Arabia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
rate of readmission (time frame: 60 days after discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2024.